GSTM1 and cancer: A meta-analysis assessing the efficacy of darbepoetin alfa initiated at Hb ≤ 10 g/dL in anemic patients with cancer revealed that more patients receiving darbepoetin alfa achieved a Hb increase ≥ 1 g/dL (fixed-effects HR, 2.07; 95% CI, 1.62–2.63) or ≥ 2 g/dL (HR, 2.91; 95% CI, 2.09–4.06) compared to those on placebo [34], with fewer transfusions needed (HR, 0.58; 95% CI, 0.44–0.77).